Monday, May 14, 2012 10:18:26 AM
Biotechs move on catalysts. You have to be patient and understand that they trade outside of fundamentals, and they are all quirky (i.e. there is a big "buy the rumor; sell the news" sentiment among most bios). They will be announcing new 407 trial data (TH-302 mono-therapy in advanced leukemias) very soon...in fact on Wednesday the abstracts will be released.
Aside from that, 2H12 and 1Q13 are going to be very big for THLD.
Price targets are high, expectations are high, but this is trading low in its trading channel right now and this is a good point to add more, or hold.
You certainly shouldn't sell here if you're thinking of doing so.
Anyway I hope this helps. Be patient, understand that some very knowledgeable people are in this (baba, triad from yahoo, tredleon, etc. etc.) and just stay put. It will pay off in the end.
Many people who know their stuff think this is a double from here within a year..that would be an AMAZING return.
Recent MTEM News
- Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patien • GlobeNewswire Inc. • 04/09/2024 12:11:00 PM
- Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 03/29/2024 12:21:08 PM
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement • GlobeNewswire Inc. • 03/28/2024 12:11:00 PM
- Molecular Templates, Inc. Provides Interim Update • GlobeNewswire Inc. • 03/04/2024 01:11:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 01:39:50 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:45:31 PM
- Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/08/2024 10:55:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:49:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:34:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:32:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:04:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:13:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:12:59 PM
- Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 11/13/2023 09:11:00 PM
- Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors • GlobeNewswire Inc. • 11/02/2023 08:11:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 08:14:59 PM
- Molecular Templates to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/01/2023 08:12:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:46:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:46:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:46:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:45:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:45:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:12:14 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/06/2023 09:08:31 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM